secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001171843-23-005063
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience Q2 revenue $28.8M; adj. op. income up to $3.6M; guides FY23 $116-120M
--------------------------------------------------------------------------------

- Q2 revenue $28.8M (-1% YoY) as discontinued product headwinds ($1.6M) offset new product growth.
- GAAP op. income $0.8M (prior year included $4.9M litigation reversal); adj. op. income rose to $3.6M from $3.1M.
- Net loss $1.0M ($0.02 loss/share) vs. net income $2.4M; adjusted EPS $0.04 vs. $0.05.
- H1 cash from ops $5.4M; net debt reduced $5.4M YTD to $37.8M.
- FY2023 guidance: revenue $116-120M, gross margin ~60%, adj. EBITDA margin 15-17%, net leverage ~2x.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184323005063/0001171843-23-005063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184323005063/f8k_080823.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-005063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer